Quarterly ResultAug 5, 2026, 04:21 PM
LifeMD Q2 Revenue $47.3M; Adjusted EBITDA Loss $3.5M; FY Guidance Cut
AI Summary
LifeMD reported Q2 2026 revenue of $47.3 million, meeting its guidance range, but an adjusted EBITDA loss of $3.5 million, which was below its guided range. The company saw strong subscriber growth and improved gross margin, driven by a shift to branded GLP-1 therapies and in-house pharmacy scaling. However, it revised its full-year 2026 revenue and adjusted EBITDA guidance downwards, while still expecting a return to positive adjusted EBITDA in the second half of 2026.
Key Highlights
- Q2 2026 revenue was $47.3 million, within guidance of $47M-$50M.
- Adjusted EBITDA loss was $3.5 million, improving 21% sequentially.
- Gross margin expanded to 89% from 86% in Q2 2025.
- Weight Management Program subscribers grew to 108,000; total active subscribers increased 20% YoY to 356,000.
- Exited Q2 with $25.1 million cash, no debt, and $30 million available credit.
- Full-year 2026 revenue guidance revised to $205.5M-$212.5M (previously $220M-$230M).
- Full-year 2026 adjusted EBITDA guidance revised to negative $6.0M to breakeven (previously $12M-$17M).
- Expects Q4 2026 exit revenue run rate of $250 million and $22 million annualized adjusted EBITDA.
Price Impact
More from LFMD